In the combination study , 100 % of the patients in the dupilumab group , as compared with 50 % of those who received topical glucocorticoids with placebo injection , met the criterion for EASI-50 ( P = 0.002 ) , despite the fact that patients who received dupilumab plus glucocorticoids used less than half the amount of topical glucocorticoids used by those who received placebo plus the topical medication ( P = 0.16 ) .